Biopharma BD teams are speeding into the fast lane — cash in hand — as dealmaking continues to heat up in Q1 offensive
The charts for dealmaking in biopharma now are being redrawn as the industry heads up into record-setting territory.
Our numbers cruncher Chris Dokomajilar, who runs DealForma, assessed the figures for Q1 the other day and came up with $38 billion in total — upfront, equity and milestones — from 282 deals. That’s up from the last record, $33 billion in Q4 2018, from 324 deals.
Cash out of those deals came in at a chart-topping $3.9 billion, up a tick from $3.8 billion at the end of 2018 and a match with the previous record in 2012, which presaged a dip for the industry.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
